Русский
Possibilities of using a fixed combination of alogliptin and pioglitazone in patients with type 2 diabetes mellitus in everyday clinical practice
DOI: https://dx.doi.org/10.18565/pharmateca.2024.2.99-104
Elsukova O.S., Nikitina E.A., Chuprova A.V., Kaysina O.A.
Kirov State Medical University, Kirov, Russia
Background. Due to the progressive course of type 2 diabetes mellitus (DM2), not all patients can achieve target levels of carbohydrate metabolism during monotherapy with glucose-lowering drugs.
Objective. Evaluation of the indicators of carbohydrate metabolism in DM2 patients using a fixed combination of alogliptin and pioglitazone in everyday clinical practice.
Methods. 30 DM2 patients aged from 22 to 72 years (mean age – 50.9±11.4 years) were examined. The state of carbohydrate metabolism was assessed by the of glycated hemoglobin (HbA1c), fasting glycemia and postprandial glycemia levels. The studied parameters were recorded initially and over time after 6 months against the background of combination therapy with alogliptin 25 mg/day and pioglitazone 30 mg/day, with addition of metformin at a dose of 2000 mg/day. The development of symptomatic hypoglycemic conditions and severe hypoglycemia was analyzed.
Results. By the end of the follow-up period, an improvement was noted in all indicators of carbohydrate metabolism – HbA1c decreased from 9.0±1.6 to 6.7±0.7% (p<0.001), fasting glycemia – from 9.1±1.7 to 6, 1±0.8 mmol/l (p<0.001), postprandial glycemia – from 10.3±2.3 to 7.8±0.7 mmol/l (p<0.001). No hypoglycemic conditions or severe hypoglycemia were recorded.
Conclusion. The results of the study confirm the effectiveness and safety of the use of fixed combination of alogliptin 25 mg and pioglitazone 30 mg in DM2 patients in everyday clinical practice.
Objective. Evaluation of the indicators of carbohydrate metabolism in DM2 patients using a fixed combination of alogliptin and pioglitazone in everyday clinical practice.
Methods. 30 DM2 patients aged from 22 to 72 years (mean age – 50.9±11.4 years) were examined. The state of carbohydrate metabolism was assessed by the of glycated hemoglobin (HbA1c), fasting glycemia and postprandial glycemia levels. The studied parameters were recorded initially and over time after 6 months against the background of combination therapy with alogliptin 25 mg/day and pioglitazone 30 mg/day, with addition of metformin at a dose of 2000 mg/day. The development of symptomatic hypoglycemic conditions and severe hypoglycemia was analyzed.
Results. By the end of the follow-up period, an improvement was noted in all indicators of carbohydrate metabolism – HbA1c decreased from 9.0±1.6 to 6.7±0.7% (p<0.001), fasting glycemia – from 9.1±1.7 to 6, 1±0.8 mmol/l (p<0.001), postprandial glycemia – from 10.3±2.3 to 7.8±0.7 mmol/l (p<0.001). No hypoglycemic conditions or severe hypoglycemia were recorded.
Conclusion. The results of the study confirm the effectiveness and safety of the use of fixed combination of alogliptin 25 mg and pioglitazone 30 mg in DM2 patients in everyday clinical practice.
About the Autors
Corresponding author: Elena A. Nikitina, Cand. Sci. (Med.), Associate Professor at the Department of Internal Medicine, Kirov State Medical University, Kirov, Russia; nikitinae1991@mail.ru
Similar Articles
